We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02315768
Recruitment Status : Active, not recruiting
First Posted : December 12, 2014
Last Update Posted : July 5, 2022
Pharmacyclics LLC.
Information provided by (Responsible Party):
Thomas Kipps, University of California, San Diego

Brief Summary:
The purpose of the study is to determine whether ibrutinib in combination with GA101 - Obinutuzumab might be useful for the treatment of CLL. This study will evaluate if ibrutinib in combination with GA101 - Obinutuzumab can reduce the amount of cancerous cells in body.

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukemia Drug: GA101 Drug: ibrutinib Phase 1 Phase 2

Detailed Description:

This is an open label phase IB/II clinical trial designed to determine the safety and clinical activity of Ibrutinib in combination with GA101 - Obinutuzumab. Safety, tolerability and dose-limiting toxicities (DLTs) will be evaluated during the initial cycle of treatment (Cycle 1; Day 1-28) as part of the phase Ib of this study (safety run-in).

In the phase II the response rate will be determined in all subjects that have received treatment. The study will enroll 32 subjects previously untreated who have active disease requiring treatment (as defined by IWCLL 2008 criteria for initiation of therapy). The study will include a Screening Phase, a Treatment Phase, and a Follow-up Phase. The Screening Phase assessments will be performed within 28 days prior to treatment. The Treatment Phase will extend from first dose until completion of all planned cycles of treatment (#6) or study drug discontinuation.

All subjects will receive Ibrutinib 420 mg (3 x 140-mg capsules) orally once daily for up to 6 cycles. The treatment with Ibrutinib will continue after cycle 6 for the following 3 years until disease progression, unacceptable toxicity or other reason for treatment discontinuation.

Subjects will undergo response assessment two months after completion of the study treatment. The initial follow-up evaluations will be made (after the response assessment) every 3 months during 9 months and later every 6 months until initiation of new treatment for CLL, consent withdrawal or death. During the long-term follow-up phase, subjects will be followed for survival (PFS, TFS and OS). The long-term follow-up phase will continue until disease progression, death, loss to follow up, consent withdrawal, or study end, whichever occurs first.

An evaluation of the End of Study will be performed due to initiation of new treatment for CLL or withdrawal of consent.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib/II Study of Ibrutinib in Combination With GA101 - Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients Over 65 Years of Age or With Comorbidities That Preclude the Use of Chemotherapy Based Treatment. GA101+Ibrutinib
Study Start Date : November 2015
Estimated Primary Completion Date : November 2023
Estimated Study Completion Date : November 2023

Arm Intervention/treatment
Experimental: GA101+ibrutinib

Ibrutinib 420 mg (140 mg capsules 3 times) orally once daily for up to 6 cycles.

GA101 (Obinutuzumab) by Intravenous infusion for up to 6 cycles (28 day cycles) as follows:

  • Cycle 1, Day 1,100 mg GA101 obinutuzumab will be administered.
  • Cycle 1, Day 2, 900 mg of GA101 obinutuzumab will be administered.
  • Cycle 1, Days 8 and 15,1,000 mg of GA101 obinutuzumab will be administered.
  • Cycles 2-6, Day 1, 1,000 mg of GA101 obinutuzumab will be administered.
Drug: GA101
Other Name: Obinutuzumab

Drug: ibrutinib

Primary Outcome Measures :
  1. Phase IB Evaluate the safety, tolerability and dose limiting toxicity (DLT) of Ibrutinib in combination with Obinutuzumab in previously untreated CLL subjects. [ Time Frame: 4 weeks ]
  2. Phase II Determine the overall response rate of Ibrutinib in combination with Obinutuzumab in previously untreated subjects with CLL. [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Determine progression-free survival (PFS), treatment-free survival (TFS) and overall survival (OS) in previously untreated CLL subjects that will receive treatment with Ibrutinib in combination with Obinutuzumab. [ Time Frame: 2 years ]
  2. Negative minimal residual disease (MRDneg) [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of CLL
  2. Indication for treatment as defined by the International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) Guidelines
  3. No previous treatment for CLL
  4. Males and females 65 years of age and older. Subjects under 65 years of age that meet any of the following criteria:

    A. Documented refusal to be treated with chemotherapy agents B. Subjects that are not candidates for treatment with chemotherapy based on poor performance status (ECOG g>= 2), Cumulative Illness Rating Scale (CIRS score) >= 6 or creatinine clearance less than 70 mL/min

  5. Adequate hematologic, hepatic, and renal function
  6. Anticipated survival of at least 6 months
  7. Effective contraception is required while receiving Ibrutinib in combination with GA101-Obinutuzumab. For women of childbearing potential and men, effective contraception is required while receiving GA101-Obinutuzumab and for 365 days (12 months) after the last dose of the study drug

Exclusion Criteria:

  1. Pregnant or nursing women
  2. Treatment with chemotherapy, monoclonal antibodies, or biological agents (e.g. lenalidomide) other than the investigational agents during the time of participation in this trial
  3. Grade 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
  4. Severe or debilitating pulmonary disease
  5. Participation in any investigational drug study within 28 days prior to initiation of treatment within this protocol.
  6. History of second malignancy, other than non-melanoma skin cancer or in situ carcinoma of the cervix or the breast, unless the tumor was successfully treated at least 2 years before trial entry and with no evidence of relapse or active cancer.
  7. Active symptomatic fungal, bacterial and/or viral infection including evidence of infection with HIV, human T-cell leukemia virus 1 (HTLV-1) seropositive status.
  8. Evidence of active acute or chronic Hepatitis B (HBV)
  9. Evidence of active Hepatitis C (HCV): subjects with positive hepatitis C serology and positive HCV RNA test
  10. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
  11. Known hypersensitivity to any of the study drugs
  12. Major surgery (within 4 weeks prior to the start of Cycle 1), except for procedures that are performed for diagnostic purposes
  13. Vaccination with a live vaccine within 28 days of the initiation of treatment.
  14. Concomitant use of warfarin or other Vitamin K antagonists
  15. Requirement to receive treatment with a strong cytochrome P450 (CYP) 3A inhibitor
  16. Chronic liver disease with hepatic impairment (Child-Pugh class B or C)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02315768

Layout table for location information
United States, California
UCSD Moores Cancer Center
La Jolla, California, United States, 92093
Sponsors and Collaborators
University of California, San Diego
Pharmacyclics LLC.
Layout table for investigator information
Principal Investigator: Thomas J. Kipps, MD, PhD University of California, San Diego
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Thomas Kipps, Deputy Director, University of California, San Diego
ClinicalTrials.gov Identifier: NCT02315768    
Other Study ID Numbers: 141106
First Posted: December 12, 2014    Key Record Dates
Last Update Posted: July 5, 2022
Last Verified: July 2022
Keywords provided by Thomas Kipps, University of California, San Diego:
Chronic Lymphocytic Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Chronic Disease
Disease Attributes
Pathologic Processes
Antineoplastic Agents, Immunological
Antineoplastic Agents